Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab + cisplatin + carboplatin + fluorouracil
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Cetuximab, a chimeric monoclonal antibody targeting the epidermal growth factor receptor (EGFR), is combined with platinum-based chemotherapy agents (cisplatin or carboplatin) and fluorouracil for the first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck. Cetuximab inhibits EGFR-mediated signaling, leading to reduced tumor cell proliferation and survival. Cisplatin and carboplatin are platinum-containing chemotherapeutic agents that cause DNA crosslinking and apoptosis, while fluorouracil is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis. This combination has been shown to improve overall survival compared to chemotherapy alone in this patient population[1][2][3].
- Other names
- cetuximab + cisplatin + carboplatin + 5-fluorouracil
02
Targets
Beyond the preview
Go deeper on cetuximab + cisplatin + carboplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab + cisplatin + carboplatin + fluorouracil.